Efficacy and safety of isradipine in hypertension

A. M.M. Shepherd, A. A. Carr, M. Davidov, J. Hamilton, H. Schnaper, M. Velasquez, B. Brockway, L. M. Prisant, B. Hamilton, L. Gonasun

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Of the calcium channel blocking drugs, only verapamil is approved in the United States for treatment of hypertension. Isradipine is a 1,4-dihydropyridine calcium blocker that may be given on a twice-daily basis. It causes peripheral vasodilation with minimal cardiodepressant activity. We undertook a double-blind, parallel group randomized, multicenter study of 203 hypertensive subjects to examine the efficacy and safety of isradipine in treatment of hypertension. Subjects were given 0, 2.5, 5, 7.5, or 10 mg isradipine twice daily for up to 5 weeks. There was a significant dose-response relationship between isradipine dose and decrease in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Isradipine 15 mg/day reduced supine pressure by 16/15 mm Hg in patients with starting DBP < 105 mm Hg and by 38/22 mm Hg in those with starting DBP ≥ 105 mm Hg. There was no significant orthostatic fall in blood pressure at any dose. Heart rate (HR) increased on an average by only a maximum of four beats/min. The drug was slightly more effective in the elderly in the standing position than in the young in the standing position. Adverse effects were mild, and only six patients were discontinued from the study because of adverse effects. Isradipine appears to be a safe, effective drug in monotherapy of hypertension at a wide range of patient ages.

Original languageEnglish (US)
Pages (from-to)580-585
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume13
Issue number4
DOIs
StatePublished - Jan 1 1989

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Efficacy and safety of isradipine in hypertension'. Together they form a unique fingerprint.

Cite this